GlassScriptPhysician profile
Darla R Rorick
NPI 1942659420
$1,736.77
in general payments reported to CMS, 2019-2025
25 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $75.29 · 2023: $135 · 2024: $360 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $235.58 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $227.55 | 2024-2025 | |
| Alkermes, INC. | $192.33 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Lilly USA, LLC | $146.16 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Neurocrine Biosciences, INC. | $130.19 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $101.78 | 2024-2025 | Fanapt |
| Lundbeck LLC | $74.82 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $72.13 | 2024-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.57 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $66.55 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $63.59 | 2025 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $50.70 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $47.66 | 2024 | |
| Collegium Pharmaceutical, INC. | $47.38 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $43.27 | 2023 | Trelegy Ellipta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $29.99 | 2025 | Sublocade |
| Pfizer INC. | $22.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.71 | 2025 | Trintellix |
| Novo Nordisk INC | $17.94 | 2025 | Ozempic, Rybelsus |
| Idorsia Pharmaceuticals US INC | $16.21 | 2023 | Quviviq |
| Exact Sciences Corporation | $15.40 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $15.13 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.14 | 2022 | |
| Corium, LLC | $4.81 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darla Rorick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.